1. Generics Bulletin
  2. >>Policy & Regulation
  3. >>Drug Pricing

Incoming US FTC Chair Endorses Agency Report Challenging PBM Generic Drug Markups

 
• By Cathy Kelly

Chairman-designee Andrew Ferguson likely will continue the commission’s investigation of PBMs during the next administration.

Big PBMs generated more than $7bn from specialty generic markups. (Citeline/Shutterstock)

The Federal Trade Commission’s second interim staff report on its ongoing investigation of potential pharmacy benefit manager misdeeds is a parting shot by outgoing FTC chair Lina Khan that also was endorsed by her designated successor, Andrew Ferguson.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

Governor Newsom Expands Discounted Naloxone Availability To All Californians

 
• By Adam Zamecnik

After the product’s initial launch in May 2024, California’s government has now expanded the availability of its CalRx-branded generic OTC Narcan to all of its citizens.

Optum Rx Remodels Payment Model To Favor Generics – A Peace Offering For FTC?

 
• By Urtė Fultinavičiūtė

Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.

Walmart Pursues Generics Industry Leaders Over Price-Fixing

 
• By Dave Wallace

Walmart has launched an attack on a host of industry-leading generics firms over historical price-fixing allegations, with the US retail giant seeking treble damages from a Pennsylvania district court.

Sandoz Suggests Coherus’ Cimerli Strategy Was ‘Unsustainable’

 
• By Dave Wallace

In the wake of Formycon’s recent announcement that US marketing partner Sandoz would be pausing commercialization of the Cimerli rival to Lucentis that it recently took over from Coherus, Sandoz management has offered a few more details on its plans for the ranibizumab biosimilar.

More from Generics Bulletin

US FDA Shows Support For Generic Drug User Fee Goals Amid Cutbacks

 
• By Michael McCaughan

The FDA struck an upbeat tone during its annual Generic Drugs Forum despite an unprecedented period of cutbacks and disruptions and reiterated a desire to continue meeting user fee goals.

Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance

 
• By Dave Wallace

Aeon Biopharma has picked up Revance Therapeutics executive Rob Bancroft to serve as its new CEO as it continues to pursue a biosimilar version of Botox. Meanwhile, Coherus has lost its chief commercial officer, as Viatris, Sandoz and Medicines for Ireland have announced new appointments.

OGD’s Policy Office Cut To Have ‘Profound’ Impact On New Generic Approvals, Warns Former FDA Head Gottlieb

 
• By Urtė Fultinavičiūtė

The elimination of the policy division at the Office of Generic Drugs, tariffs, the Section 232 investigation, and a new executive order to promote lower drug prices seem to both cause and purport to solve the same problem: supply chain disruption.